JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Cassava Sciences (SAVA – Research Report) today and set a price target of $215.00. The company’s shares closed last Tuesday at $117.30.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 29.6% and a 36.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Actinium Pharmaceuticals, and Silverback Therapeutics.
Cassava Sciences has an analyst consensus of Strong Buy, with a price target consensus of $154.80.
See today’s analyst top recommended stocks >>
Cassava Sciences’ market cap is currently $4.63B and has a P/E ratio of -281.20. The company has a Price to Book ratio of 15.06.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SAVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Read More on SAVA:
